Dilaudid 8mg – The Complete Medical Guide

Dilaudid 8mg (hydromorphone hydrochloride) is a high-potency opioid analgesic classified as a Schedule II controlled substance. As one of the strongest commercially available oral opioid formulations, it’s approximately 5-7 times more potent than morphine milligram-for-milligram. This high-dose tablet is reserved for severe, refractory pain in opioid-tolerant patients, typically in cancer pain management or end-of-life care.

Dilaudid 8 mg

Medical Uses & Indications

FDA-Approved Uses

 Severe chronic pain management (Cancer-related, palliative care)
 Acute pain (Major trauma, post-surgical when other opioids fail)
 Breakthrough pain episodes (In opioid-tolerant patients)

Key Clinical Features

• Potency: 5-7× morphine (oral)
• Onset/Duration:

• Oral: 30 min onset, 3-4 hr duration

• IV: 5 min onset, 2-3 hr duration
  • DEA Classification: Schedule II (High abuse potential)

Pharmacology & Effects

Mechanism of Action

• Pure μ-opioid receptor agonist
• Minimal active metabolites (unlike morphine)

Therapeutic Effects

Rapid, powerful analgesia
Reduced affective pain component
Mild anxiolysis in terminal patients

Abuse Potential

• Street names: Dust, Footballs, Smack
• Common routes of abuse: Injection, snorting
• Overdose risk: Extreme with non-tolerant users

Dosing & Administration

Standard Dosing

• Opioid-tolerant adults: 2-8mg every 3-4 hours PRN
• Maximum recommended: 32mg/day (oral)

Conversion Guidelines

Critical Safety Notes

 Absolute contraindication in opioid-naïve patients
 Must titrate carefully in renal impairment
 Tablets should never be crushed/chewed

Safety Profile

Common Side Effects

• Respiratory depression (dose-dependent)
• Severe constipation (prophylaxis required)
• Nausea/vomiting
• CNS depression

Black Box Warnings

 Life-threatening respiratory depression
 Accidental ingestion risk
 Addiction/dependence potential
 Neonatal opioid withdrawal syndrome

Overdose Management

Recognition

• Respiratory rate <8
• Pinpoint pupils
• Unresponsiveness
• Cyanosis

Emergency Protocol

1. Administer naloxone (0.4-2mg IV/IM/IN)

2. Support ventilation

3. Repeat naloxone q2-3min PRN

4. Continuous monitoring (may require infusion)

Harm Reduction Strategies

1. Locked storage (Prevents diversion)

2. Naloxone co-prescribing (Mandatory in many states)

3. Medication disposal systems

4. Regular PDMP monitoring

Clinical Alternatives

For Chronic Pain

• Methadone (For opioid rotation)
• Fentanyl patches (Stable blood levels)
• Buprenorphine (Safer profile)

For Acute Pain

• Oxycodone CR
• Morphine sulfate ER
• Multimodal analgesia

Special Populations